About Viking Therapeutics (NASDAQ:VKTX)
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-5.96
Forward P/E Ratio-10.70
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$0.38 per share
Price / Book12.39
EPS (Most Recent Fiscal Year)($0.79)
Return on Equity-276.21%
Return on Assets-129.79%
Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions
What is Viking Therapeutics' stock symbol?
Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."
How were Viking Therapeutics' earnings last quarter?
Viking Therapeutics (NASDAQ:VKTX) released its quarterly earnings results on Wednesday, March, 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.18) by $0.04. View Viking Therapeutics' Earnings History.
When is Viking Therapeutics' next earnings date?
What price target have analysts set for VKTX?
3 Wall Street analysts have issued 12 month target prices for Viking Therapeutics' stock. Their predictions range from $8.00 to $11.00. On average, they expect Viking Therapeutics' stock price to reach $9.00 in the next year. View Analyst Ratings for Viking Therapeutics.
Who are some of Viking Therapeutics' key competitors?
Some companies that are related to Viking Therapeutics include MediciNova (MNOV), Isotechnika Pharma (AUPH), ProMetic Life Sciences (PFSCF), Sinovac Biotech (SVA), Concert Pharmaceuticals (CNCE), Synergy Pharmaceuticals (SGYP), Depomed (DEPO), Syros Pharmaceuticals (SYRS), Cara Therapeutics (CARA), Albireo Pharma (ALBO), Kala Pharmaceuticals (KALA), Corium International (CORI), Cytokinetics (CYTK), Mersana Therapeutics (MRSN), Corbus Pharmaceuticals (CRBP), GTX (GTXI), Dermira (DERM) and Clearside Biomedical (CLSD).
Who are Viking Therapeutics' key executives?
Viking Therapeutics' management team includes the folowing people:
- Dr. Brian Lian, Pres, CEO & Director (Age 52)
- Mr. Michael Morneau, CFO & Principal Accounting Officer (Age 53)
- Mr. Gregory S. Zante CPA, VP of Fin. & Operations (Age 47)
- Ms. Amy Broidrick, Sr. VP of Corp. Devel.
- Dr. Hiroko Masamune Ph.D., Sr. VP of Pharmaceutical Devel. (Age 61)
When did Viking Therapeutics IPO?
(VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.
Has Viking Therapeutics been receiving favorable news coverage?
Press coverage about VKTX stock has trended positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Viking Therapeutics earned a news impact score of 0.25 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 47.45 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Viking Therapeutics?
Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viking Therapeutics' stock price today?
One share of VKTX stock can currently be purchased for approximately $4.71.
How big of a company is Viking Therapeutics?
Viking Therapeutics has a market capitalization of $231.75 million. The biotechnology company earns $-20,570,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Viking Therapeutics employs 14 workers across the globe.
How can I contact Viking Therapeutics?
Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]
MarketBeat Community Rating for Viking Therapeutics (VKTX)MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote "Outperform" if you believe VKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VKTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Viking Therapeutics (NASDAQ:VKTX) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Viking Therapeutics (NASDAQ VKTX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 18.34%
Viking Therapeutics (NASDAQ VKTX) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/15/2016||Matthew W Foehr||Director||Buy||13,000||$1.21||$15,730.00||39,250|| |
|4/13/2016||Matthew W Foehr||Director||Buy||20,000||$1.24||$24,800.00||26,250|| |
Viking Therapeutics (NASDAQ VKTX) News Headlines
Viking Therapeutics (NASDAQ:VKTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Viking Therapeutics (NASDAQ:VKTX) Income Statement, Balance Sheet and Cash Flow Statement
Viking Therapeutics (NASDAQ VKTX) Stock Chart for Sunday, April, 22, 2018